Healthcare >> Analyst Interviews >> August 20, 2014
Cancer Immunotherapy a Top Focus in Biotechnology Sector
Y. Katherine Xu, Ph.D., joined William Blair & Company, L.L.C. in March 2011 as a Biotechnology Analyst. Dr. Xu previously was Senior Vice President and Senior Biotechnology Analyst at Wedbush Securities, Vice President and Senior Biotechnology Analyst at Credit Suisse, and a Senior Biotechnology Analyst at Pacific Growth Equities. Dr. Xu was recognized by the Financial Times/StarMine "World's Top Analysts" listing, ranking number seven overall for stock picking in the United States in 2010, and number two for stock picking in biotechnology in 2011. She received the number two ranking in The Wall Street Journal's "Best on the Street" listing in 2011 as well. Before her move to equity research, Dr. Xu worked in investment banking for two years. Dr. Xu holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively, and worked on a postdoctoral project in bioinformatics at the Department of Mathematics, Stanford University. She attended Peking University in Beijing and Kalamazoo College in Michigan, where she gained her B.A. with honors. Profile
TWST: The biotech space is rather broad. Is there a particular area you're focusing on?
Dr. Xu: We like to approach various disease areas in a comprehensive way. Historically we have